Epithelial barrier leak in gastrointestinal disease and multiorgan failure

Journal of Epithelial Biology and Pharmacology

Volumn 5, Issue SPEC. ISSUE, 2012, Pages 13-18

  Farrell, Christopher P ^a   Barr, Maura ^a   Mullin, James M ^a   Lande, Leah ^a   Zitin, Marc ^a  

^a LANKENAU HOSPITAL   (United States)

Author keywords

Inflammatory bowel disease; Multiorgan dysfunction syndrome; Tight junctions

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URSODEOXYCHOLIC ACID;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTISM; BACTERIAL PERITONITIS; CAUSE OF DEATH; CELIAC DISEASE; CHRONIC GASTRITIS; CLINICAL EFFECTIVENESS; CROHN DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GLUTEN FREE DIET; HELICOBACTER INFECTION; HEPATITIS C; HUMAN; IMMUNOREACTIVITY; INTESTINE MUCOSA PERMEABILITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OXIDATIVE STRESS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SEPSIS; TIGHT JUNCTION; ULCERATIVE COLITIS;

EID: 84856619519     PISSN: None     EISSN: 18750443     Source Type: Journal    
DOI: 10.2174/1875044301205010013     Document Type: Article

References (67)

1. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002; 34: 385-96.
2. Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003; 18: 479-97.
3. Sander GR, Cummins AG, Henshall T, Powell BC. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett 2005; 579: 4851-5.
4. Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signaling involved in intestinal barrier function. Gut 2003; 52: 218-23.
5. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2010; [Epub ahead of print].
6. Edelblum KL, Turner JR. The tight junction in inflammatory disease: communication breakdown. Curr Opin Pharmacol 2009; 9: 715-20.
7. Welcker K, Martin A, Kölle P, Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004; 9: 456-60.
8. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol 2007; 23: 379-83.
9. Ma TY, Iwamoto GK, Hoa NT, et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NFkappa B activation. Am J Physiol Gastrointest Liver Physiol 2004; 286: G367-76.
10. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002; 97: 2000-4.
11. Nejdfors P, Wang Q, Ekelund M, et al. Increased colonic permeability in patients with ulcerative colitis: an in vitro study. Scand J Gastroenterol 1998; 33: 749-53.
12. Gitter AH, Wullstein F, Fromm M, Schulzke JD. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001; 121: 1320-8.
13. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 100-13.
14. Taha Y, Carlson M, Thorn M, Loof L, Raab Y. Evidence of local eosinophil activation and altered mucosal permeability in collagenous colitis. Dig Dis Sci 2001; 46: 888-97.
15. Fukuda Y, Bamba H, Okui M, et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion 2001; 63: 93-6.
16. Borch K, Sjöstedt C, Hannestad U, Söderholm JD, Franzén L, Mårdh S. Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability. Dig Dis Sci 1998; 43: 749-53.
17. Fedwick JP, Lapointe TK, Meddings JB, Sherman PM, Buret AG. Helicobacter pylori activates myosin chain light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability. Infect Immun 2005; 73: 7844-52.
18. Lytton SD, Fischer W, Nagel W, Haas R, Beck FX. Production of ammonium by Helicobacter pylori mediates occluding processing and disruption of tight junctions in Caco-2 cells. Microbiology 2005; 151: 3267-76.
19. Juvonen PO, Alhava EM, Takala JA. Gut permeability in patients with acute pancreatitis. Scand J Gastroenterol 2000; 35: 1314-8.
20. Liu H, Li W, Li J, Yu W. Early gut mucosal dysfunction in patients with acute pancreatitis. Pancreas 2008; 36: 192-6.
21. Yasuda T, Takeyama Y, Ueda T, et al. Breakdown of intestinal mucosa via accelerated apoptosis increases intestinal permeability in experimental severe acute pancreatitis. J Surg Res 2006; 135: 18-26.
22. Nagpal K, Minocha VR, Agrawal V, Kapur S. Evaluation of intestinal mucosal permeability in patients with acute pancreatitis. Am J Surg 2006; 192: 24-8.
23. Ersöz G, Aydin A, Erdem S, Yüksel D, Akarca U, Kumanlioglu K. Intestinal permeability in liver cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 409-12.
24. Cariello R, Federico A, Sapone A, et al. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 2010; 42: 200-4.
25. Kim JW, Jeon WK, Yun JW, et al. Intestinal permeability in patients with viral and alcoholic liver disease. Korean J Gastroenterol 2004; 43: 104-11.
26. Ancel D, Barraud H, Peyrin-Biroulet L, Bronowicki JP. Intestinal permeability and cirrhosis. Gastroenterol Clin Biol 2006; 30: 460-8.
27. Basuroy S, Sheth P, Mansbach CM, Rao RK. Acetaldehyde disrupts tight junctions and adherens junctions in human colonic mucosa: protection by EGF and L-glutamine. Am J Physiol Gastrointest Liver Physiol 2005; 289: G367-75.
28. Scarpellini E, Valenza V, Gabrielli M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010; 105: 323-7.
29. Di Leo V, Venturi C, Baragiotta A, Martines D, Floreani A. Gastroduodenal and intestinal permeability in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2003; 15: 967-73.
30. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-5.
31. Bekker V, O'Brien TR, Chanock S. Population genetics and comparative genetics of CLDN1, a gene involved in hepatitis C virus entry. Hum Hered 2009; 67: 206-16.
32. Benedicto I, Molina-Jiménez F, Bartosch B, et al. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 2009; 83: 8012-20.
33. Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 2003; 9: 143-51.
34. Heitbrink F, Besselink MG, Renooij W, et al. Systemic inflammation increases intestinal permeability during experimental human endotoxemia. Shock 2009; 32: 374-8.
35. Jørgensen VL, Nielsen SL, Espersen K, Perner A. Increased colorectal permeability in patients with severe sepsis and septic shock. Intensive Care Med 2006; 32: 1790-6.
36. Guttman JA, Finlay BB. Tight junctions as targets of infectious agents. Biochim Biophys Acta 2009; 1788: 832-41.
37. Daniels JJ, Autenrieth IB, Goebel W. Interaction of Listeria monocytogenes with the intestinal epithelium. FEMS Microbiol Lett 2000; 190: 323-8.
38. Lecuit M. Understanding how Listeria monocytogenes targets and crosses host barriers. Clin Microbiol Infect 2005; 11: 430-6.
39. Hanajima-Ozawa M, Matsuzawa T, Fukui A. Enteropathogenic Escherichia coli, Shigella flexneri, and Listeria monocytogenes recruit a junctional protein, zonula occludens-1, to actin tails and pedestals. Infect Immun 2007; 75: 565-73.
40. Tepper RE, Simon D, Brandt LJ, Nutovits R, Lee MJ. Intestinal permeability in patients infected with the human immunodeficiency virus. Am J Gastroenterol 1994; 89: 878-82.
41. Pernet P, Vittecoq D, Kodjo A, et al. Intestinal absorption and permeability in human immunodeficiency virus-infected patients. Scand J Gastroenterol 1999; 34: 29-34.
42. Sharpstone D, Neild P, Crane R, et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 1999; 45: 70-6.
43. Becker K, Lindner C, Frieling T, Niederau C, Reinauer H, Häussinger D. Intestinal protein leakage in the acquired immunodeficiency syndrome. J Clin Gastroenterol 1997; 25: 426-8.
44. Carratù R, Secondulfo M, de Magistris L, et al. Altered intestinal permeability to mannitol in diabetes mellitus type I. J Pediatr Gastroenterol Nutr 1999; 28: 264-9.
45. Secondulfo M, Iafusco D, Carratù R, et al. Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig Liver Dis 2004; 36: 35-45.
46. Secondulfo M, de Magistris L, Sapone A, Di Monda G, Esposito P, Carratù R. Intestinal permeability and diabetes mellitus type 2. Minerva Gastroenterol Dietol 1999; 45: 187-92.
47. Ventura MT, Polimeno L, Amoruso AC, et al. Intestinal permeability in patients with adverse reactions to food. Dig Liver Dis 2006; 38: 732-6.
48. Doig CJ, Sutherland LR, Sandham JD, Fick GH, Verhoef M, and Meddings JB. Increased epithelial permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. Am J Respir Crit Care Med 1998; 158: 444-51.
49. Fink MP, Delude RL. Epithelial barrier dysfunction: A unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin North Am 2005; 21: 178-96.
50. Gaugler MH. A unifying system: does the vascular endothelium have a role to play in multi-organ failure following radiation exposure? BJR Suppl. 2005; 27: 100-5.
51. Soler AP, Marano CW, Bryans M, Miller RD, Garulacan LA, Mauldin SK, Stamato TD, Mullin JM. Activation of NF-kappa B is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosis. Eur J Cell Biol 1999; 78: 56-66.
52. Peralta Soler A, Mullin JM, Knudsen KA, Marano CW. Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells. Am J Physiol 1996; 270: F869-79.
53. Clark JA, Coopersmith CM. Intestinal crosstalk-a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007; 28: 384-93.
54. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Europ Heart J 2005; 26: 2368-74.
55. Gatt M, Reddy BS, Macfie J. Review article: bacterial translocation in the critically ill-evidence and methods of prevention. Aliment Pharmacol Ther 2007; 25: 741-57.
56. Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a002907. Review. PubMed PMID: 20182608; PubMed Central PMCID: PMC2827901.
57. Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol. 2010;5:119-44. Review. PubMed PMID: 20078218.
58. Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009; 1: a002584. Review. PubMed PMID: 20066090; PubMed Central PMCID: PMC2742087.
59. Zhang JB, Du XG, Zhang H, et al. Breakdown of the gut barrier in patients with multiple organ dysfunction syndrome is attenuated by continuous blood purification: effects on tight junction structural proteins. Int J Artif Organs 2010; 33: 5-14.
60. Moore FA, Moore EE, Poggetti R, et al. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma 1991; 31: 629-39.
61. Deitch EA, Xu D, Kaiser VL. Role of the gut in the development of injury-and shock-induced SIRS and MODS: the gut-lymph hypothesis, a review. Frontiers Biosci 2006; 11: 520-8.
62. Magnotti LJ, Xu DZ, Lu Q, Deitch EA. Gut-derived mesenteric lymph: A link between burn and lung injury. Arch Surg 1999; 134: 1333-41.
63. Sambol JT, White J, Horton JW, Deitch EA. Burn-induced impairment of cardiac contractile function is due to gut-derived factors transported in mesenteric lymph. Shock 2002; 18: 272-6.
64. Looney MR, Matthay MA. Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury. Crit Care 2006; 10: 239-45.
65. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
66. Alberda C, Gramlich L, Meddings J, et al. Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2007; 85: 816-23.
67. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 1625-34.